Recruiting PHASE1 INTERVENTIONAL 2-arm NCT06321484

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

A Phase 1b Study of Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cell Therapy in Recurrent Ovarian Cancer

Sponsor: Dana-Farber Cancer Institute

Conditions Clear Cell Ovarian Carcinoma Endometroid Ovarian Carcinoma Ovarian Cancer Ovarian Carcinoma Ovarian Carcinoma, Recurrent Platinum-resistant Ovarian Cancer Recurrent Ovary Cancer

Interventions Cytokine-Induced Memory-like Natural Killer Cells Interleukin 2

Updated 6 times since 2024 Last updated: Mar 2, 2026 Started: Oct 9, 2024 Primary completion: Nov 30, 2026 Completion: Oct 31, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Clear Cell Ovarian Carcinoma and Endometroid Ovarian Carcinoma, this trial is actively recruiting participants. The trial is conducted by Dana-Farber Cancer Institute and has accumulated 6 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE1
Aug 2025 — Mar 2026 [monthly]

Recruiting PHASE1
Dec 2024 — Aug 2025 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Dec 2024 [monthly]

Not Yet Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1

▶ Show 1 earlier version

Apr 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dana-Farber Cancer Institute

Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States